Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Zimmer Biomet (ZBH) stock in plain English

Free brief · no signupStart here
ZBHPublished Nov 13, 2026
Zimmer Biomet Holdings Inc
Healthcare · Medical Devices
Manufactures orthopedic implants, surgical tools, and robotic guidance systems for hospitals.
Assets:
Warsaw manufacturing hubPrimary orthopedic production and research facilities in Indiana
18,000 employeesGlobal workforce across manufacturing and specialized clinical sales
ROSA robotic fleetSurgical robots installed globally for guided joint reconstruction
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

53
OPS ScoreOperating finances
Latest quote
-1.79%$101.47
$19.20B
25.7×
$8.57B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ZBH. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Zimmer Biomet (ZBH) do?

Zimmer Biomet Holdings Inc (ZBH) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures orthopedic implants, surgical tools, and robotic guidance systems for hospitals. It designs and manufactures artificial knees, hips, and surgical robotics used in joint reconstruction procedures. It is worth $19.20B on the market and sold $8.57B over the last year.

Market cap
$19.20B
P/E ratio
25.7×
Annual sales
$8.57B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 13, 2026

Brands and businesses behind ZBH

  • ROSA: Sells robotic surgical assistants and compatible procedural instruments to hospital operating rooms.
  • Persona: Produces personalized artificial knee implants and surgical instruments sold to orthopedic centers.
  • Oxford: Manufactures partial knee replacement implants designed to repair single compartments of damaged joints.
  • G7 Acetabular System: Supplies modular hip socket replacement implants and fixation instruments to surgeons.
  • Avenir Complete: Sells femoral stems and instrumentation kits used in primary hip replacement surgeries.
  • Signature ONE: Provides patient-specific surgical guides and preoperative planning software for joint procedures.

ZBH’s flags, in plain English

Each flag is a number from Zimmer Biomet’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Wide Gross Margin

Gross margin of 61.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Low debt

Low debt, only 59% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Cheap on Cash Flow

Priced at 14.8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Growth Cooling

Sales growth slowed to 3.2% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

Questions about ZBH

How big is Zimmer Biomet?

Zimmer Biomet’s market cap is $19.20B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $8.57B: what customers paid the company over the last year, before any costs.

What is ZBH’s P/E ratio?

ZBH’s P/E ratio is 25.7×. Investors pay about 25.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ZBH?

Revenues depend heavily on elective reconstructive surgeries that hospitals can defer during staffing shortages or budget constraints. That is one risk on Zimmer Biomet’s card. Its first risk flag is Growth Cooling, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Zimmer Biomet’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ZBH’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card